Sulfasalazine probably leads to lower induction of remission compared with sulfasalazine and corticosteroids (moderate certainty).
Sulfasalazine showed no clear difference in induction of remission (CDAI <150), therapeutic response (VHI… compared with placebo (low certainty).
Sulfasalazine showed no clear difference in induction of remission (CDAI <150) (Random Effects Model) compared with placebo (moderate certainty).
Sulfasalazine probably leads to lower induction of remission (CDAI <150) compared with corticosteroids (moderate certainty).
It is very uncertain whether methotrexate + sulfasalazine changes maintenance of Remission compared with sulfasalazine (very low certainty).
It is very uncertain whether the intervention changes sulfasalazine (2 RCTs; 143 participants) (very low certainty).
It is very uncertain whether the intervention changes sulfasalazine + prednisolone (1 RCT; 57 participants) (very low certainty).
It is very uncertain whether the intervention changes sulfasalazine (1 RCT; 32 participants) (very low certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).
It is very uncertain whether mesalamine changes induction of remission (CDAI < 150) or clinical improvement ‐… compared with sulfasalazine (alone or (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in maintenance of remission compared with mesalazine or sulfasalazine (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).